UK biotech company Ingenza has joined forces with leading universities and industrial partners to participate in the ConBioChem collaboration, a translational project focused on the development of novel platform technologies for the continuous bio-production of commodity chemicals.
Clariant, a Swiss leader in specialty chemicals, and French industrial biotech company Global Bioenergies last Tuesday announced the development of a new bio-based polymer for cosmetic creams and lotions, which is derived from renewable isobutene.
Genomatica published the results of a major survey of sustainability issues in the mainstream chemical industry. The survey was conducted together with ICIS, the world’s largest petrochemical market information provider. The survey, fourth in a series they have conducted since 2009, revealed substantial advances for sustainability and renewable chemicals in general, for chemical producers, users (companies making products from basic and intermediate chemicals) and distributors.
Rome will be the Euro-mediterranean capital of the bioeconomy for a couple of days. The Italian Forum on Industrial Biotechnology and Bioeconomy (IFIB) goes to the Italian capital from 5 to 6 October at the Palazzo Rospigliosi, in front of the House of the President of the Republic.
Global Bioenergies expands in the Netherlands. The French biotech company led by Marc Delcourt signed a contribution agreement with the shareholders of Syngip B.V. to transfer all Syngip shares to Global Bioenergies S.A. The transaction’s completion remains subject to the fulfilment of several suspensive conditions including approval by the shareholders of Global Bioenergies.
“Biotech is becoming increasingly important to the mainstream chemical industry as the demand for more sustainable solutions intensifies. Biotech is especially well-suited to help with some of the industry’s biggest challenges”. To say it – in this exclusive interview with Il Bioeconomista – is Christophe Schilling, founder and CEO of Genomatica, a widely-recognized bioengineering leader for the chemical industry. The San Diego-based biotechnology company develops and licenses bio-based manufacturing processes for the production of intermediate and basic chemicals.
Since being named CEO in May 2009, Christophe Schilling has led Genomatica to widespread recognition as a leader in industrial biotechnology, with a commercialized first process, top-tier licensees, strong investors and an unrivaled string of awards for engineering (Kirkpatrick), science (EPA Presidential Green Chemistry), industry leadership (voted #1 Hottest three years in a row by Biofuels Digest), and company culture (The Scientist as a Best Place to Work). Schilling frequently speaks on industry trends at major conferences and serves as a member of the World Economic Forum Global Agenda Council on Biotechnology.
Interview by Mario Bonaccorso
Danish biotech giant Novozymes last week broke ground for its new innovation campus in Lyngby, close to the Technical University of Denmark and seven kilometers from Novozymes’ headquarters in Bagsværd.
“Scotland has under 10% of the UK population and over 30% of the land mass giving it considerably more capacity for growing biomass as feedstock for the bioeconomy. Scotland has great research capabilities, a strong base of SMEs looking to develop its bio-capabilities and the joined up support of the government with all its agencies in developing this opportunity”. Roger Kilburn, CEO IBioIC (Industrial Biotechnology Innovation Centre) Scotland, talks to Il Bioeconomista. In this long, exclusive interview, he talks about UK and Scottish bioeconomy, the role of industrial biotechnology and Brexit. “The fundamental reasons for developing the bioeconomy – he says – are the positive impact it has on sustainability, the environment and the ability to produce new and improved materials. None of these fundamentals are affected by Brexit”.
Interview by Mario Bonaccorso
Scotland is set to create waves among the global biotechnology arena as its Industrial Biotechnology Innovation Centre (IBioIC) announces over £3 million of investment across six game changing synthetic biology projects including greener skincare products, more sustainable plastics and improvements to personalised medicine therapies.
The bioeconomy is alive and is set to grow. This is the strong message coming from Vicenza, Italy, where last Thursday and Friday was held the sixth edition of IFIB, the Italian Forum on Industrial Biotechnology and Bioeconomy.
About 300 participants. Among them some of the big global companies active in the bioeconomy: Braskem, Dow, Novamont, NatureWorks, Mossi Ghisolfi, Clariant, GFBiochemicals and Carlsberg. Innovative start-ups, universities and research centers, as well as clusters such as Clib2021 (Germany), IAR Pole (France) and Bio-based Delta (Netherlands). And again: OECD, European Investment Bank, German Bioeconomy Council.
“Sustainability – Rafael Cayuela, Chief Economist at Dow Chemical, stated – is a huge technological challenge but also the single largest business opportunity of this generation”.